Identification of tumor antigens and immune subtypes in lung squamous cell carcinoma for mRNA vaccine development.

ABSTRACT:

Background

Cancer vaccines are therapies that activate the patient's own immune system by inoculating the patient with cancer-specific antigens to identify and clear cancer cells. Messenger ribonucleic acid (mRNA) vaccines have received much attention because of their ease of synthesis, relative affordability, and long-term safety, but have not been studied in lung squamous cell carcinoma (LUSC). Thus, the identification of tumor antigens is necessary to facilitate the development of mRNA vaccines for LUSC.

Methods

Genes with significant copy number amplification, the presence of gene mutations in LUSC, and genes associated with survival were identified as potential tumor antigens. Subsequently, the genes significantly correlated with the level of infiltration of 3 antigen-p

SUBMITTER: Zhao J 

PROVIDER: S-EPMC9562514 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature